KeyBanc analyst Devin Au lowered the firm’s price target on Coursera (COUR) to $11 from $12 and keeps an Overweight rating on the shares.
Coursera Therapeutics offers significant value with no debt and strong cash flow. See more on COUR stock and why it's a BUY ...
Coursera Inc (NYSE:COUR) shares tumbled 15% in after-hours trading Wednesday as the online education platform's ...
Loop Capital lowered the firm’s price target on Coursera (COUR) to $12 from $20 but keeps a Buy rating on the shares after its Q3 results ...
Coursera shares are trading lower after the company reported its third-quarter results after Thursday's closing bell. Here's ...
Online learning platform Coursera (NYSE:COUR) beat Wall Street’s revenue expectations in Q3 CY2024, with sales up 6.4% year ...
Shares of Coursera traded at what would be an all-time low after the close on Thursday following the online learning platform's cut to revenue guidance for 2024. The stock fell to $5.80, surpassing ...
Delivered third quarter revenue of $176 million Reported net cash provided by operating activities of $27.8 million; Free ...
Tesla stock moves lower after shares of the electric-vehicle maker surged 22% on Thursday, a judge grants the FTC request to ...